Tag: capital

Investment Grade Financing Supports Critical Indian Infrastructure Asset

HUNTSVILLE, AL, June 23, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform^™ drug optimization technology, is pleased to announce that Chief Executive Officer Steve Ledger will present at an upcoming FORCE Family Office investor webinar titled "New Drug Optimization Platform to Transform Parkinson’s Care.” The Event is scheduled to take place on Thursday, June 26, 2025, at 12:00 p.m. ET / 9:00 a.m. PT.

TORONTO, 23 juin 2025 (GLOBE NEWSWIRE) -- Lysander Funds Limited (« Lysander ») a annoncé aujourd’hui des réductions des frais de gestion, le remplacement d’un gestionnaire de portefeuille et la modification du niveau de risque de certains de ses organismes de placement collectif (OPC). Des détails sur ces changements sont donnés ci-après.

TORONTO, June 23, 2025 (GLOBE NEWSWIRE) -- Lysander Funds Limited (“Lysander”) announced today management fee reductions, change in portfolio manager and change in risk ratings for certain of its mutual funds.  Details of these changes are set out below.

TORONTO, June 23, 2025 (GLOBE NEWSWIRE) -- Timbercreek Financial (TSX: TF) (the “Company”) is pleased to announce that it has declared a monthly cash dividend of $0.0575 per common share (“Common Share”) of the Company to be paid on July 15, 2025 to holders of Common Shares of record on June 30, 2025.

NON DESTINÉ À LA PUBLICATION AUX ÉTATS-UNIS OU AUX AGENCES DE TRANSMISSION AMÉRICAINES

(Photo credit: Andreas Neumann)

Hong Kong, June 23, 2025 (GLOBE NEWSWIRE) -- Happy City Holdings Limited (Nasdaq: HCHL) (the “Company”), an established all-you-can-eat hotpot restaurant operator in Hong Kong , today announced the pricing of its initial public offering (the “Offering”) of 1,100,000 Class A ordinary shares (the “Class A Ordinary Shares”), at a price of $5.00 per Class A Ordinary Share (the “Offering Price”).

SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (“Cidara”) (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced its plans to commence an underwritten public offering, subject to market and other conditions, to issue and sell $250.0 million of shares of its common stock. All of the shares are being offered by Cidara. In connection with the proposed offering, Cidara expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering. There can be no assurance as to whether or when the proposed offering may be completed or as to the actual size or terms of the proposed offering.